bluebird bio Inc.

Company Overview

Bluebird bio was established in 1992. The company develops products for disease areas such as cerebral adrenoleukodystrophy, β-thalassemia, sickle cell disease and multiple myeloma, using cell and gene therapy technologies including lentiviral gene addition and (megaTAL-enabled) gene editing. In oncology, the company is focused on developing novel T cell-based immunotherapies, including CAR-T and T cell receptor (TCR) T cell therapies.

As of March 27, 2023, Zynteglo is commercially available to patients in the U.S. through a network of 12 QTCs (defined as having a signed services agreement). The company said it would scale to 40 to 50 centers by the end of 2023. Skysona is currently available through a network of three activated QTCs. Cell collection was completed for two commercial Skysona patients as of March 2023 and in March 2023, the first Skysona commercial infusion was completed.

Financial Highlights (FY 2023)

Company's Business Segments

• Product revenue : Revenues have primarily been derived from product revenues associated with the sale of ZYNTEGLO in Germany.
• Other revenue : We have recognized an immaterial amount of revenue associated with grants and collaboration agreements.